A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

Completed · Phase 3 · Has a placebo group

Conditions studied: Bleeding

In brief

The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.

Key facts

Study ID

NCT02207725

Run by

Portola Pharmaceuticals

People needed

68

Starts

2014-03-01

Expected to finish

2015-09-01

Last updated by the study team

2023-08-08

Who can join

Age: 50 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Reasonably healthy men and women aged 50 to 75

You may not qualify if…

• History of abnormal bleeding, active bleeding or risk factors for bleeding
• History of thrombosis or risk factors for thrombosis
• History of adult asthma or use of inhaled medications

Where it is running

• Celerion — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.